Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia

Psychopharmacology

Volumn 218, Issue 4, 2011, Pages 611-620

  Roser, Patrik ^a   Haussleiter, Ida S ^a   Chong, Hee Jeong ^a   Maier, Christoph ^b   Kawohl, Wolfram ^c   Norra, Christine ^a   Juckel, Georg ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CB 1 receptor; Ketamine; Mismatch negativity; NMDA; Rimonabant; Schizophrenia

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUTAMIC ACID; KETAMINE; RIMONABANT;

ADULT; ARTICLE; AUDITORY STIMULATION; COGNITION; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; EXPERIMENTAL MODEL; GLUTAMATERGIC TRANSMISSION; HUMAN; HUMAN EXPERIMENT; MALE; MISMATCH NEGATIVITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOTOMIMETIC STATES INVENTORY; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SENSORY MEMORY; VOLUNTEER;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, AUDITORY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MALE; PIPERIDINES; PROSPECTIVE STUDIES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 82955249251     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2352-y     Document Type: Article

References (69)

1. N Auclair S Otani P Soubrie F Crepel 2000 Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons J Neurophysiol 83 3287 3293 10848548 1:CAS:528: DC%2BD3cXksVGiurg%3D (Pubitemid 30408863)
2. M Ballmaier M Bortolato C Rizzetti M Zoli G Gessa A Heinz P Spano 2007 Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis Neuropsychopharmacology 32 2098 2107 17299506 10.1038/sj.npp.1301344 1:CAS:528:DC%2BD2sXhtVCisbjK (Pubitemid 47417693)
3. RM Bilder 1997 Neurocognitive impairment in schizophrenia and how it affects treatment options Can J Psychiatry 42 255 264 9114941 1:STN:280:DyaK2s3ntVSlsg%3D%3D (Pubitemid 27257123)
4. DC D'Souza 2007 Cannabinoids and psychosis Int Rev Neurobiol 78 289 326 17349865 10.1016/S0074-7742(06)78010-2
5. WA Devane L Hanus A Breuer RG Pertwee LA Stevenson G Griffin D Gibson A Mandelbaum A Etinger R Mechoulam 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1946 1949 1470919 10.1126/science.1470919 1:CAS:528:DyaK3sXpvVKntg%3D%3D (Pubitemid 23026736)
6. HM Emrich FM Leweke U Schneider 1997 Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system Pharmacol Biochem Behav 56 803 807 9130308 10.1016/S0091-3057(96)00426-1 1:CAS:528:DyaK2sXislaqs7w%3D (Pubitemid 27189767)
7. NB Farber JW Newcomer JW Olney 1998 The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease Prog Brain Res 116 421 437 9932393 10.1016/S0079-6123(08)60453-7 1:CAS:528: DyaK1cXotVCmu7g%3D (Pubitemid 28526951)
8. Y Gaoni R Mechoulam 1964 Isolation, structure and partial synthesis of an active constituent of hashish J Am Chem Soc 86 1646 1647 10.1021/ja01062a046 1:CAS:528:DyaF2cXkt1GhtLs%3D
9. C Gilles R Luthringer 2007 Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs J Psychopharmacol 21 272 282 17591655 10.1177/0269881107077733 1:CAS:528:DC%2BD2sXovFajsbk%3D (Pubitemid 46934050)
10. JA Gordon 2010 Testing the glutamate hypothesis of schizophrenia Nat Neurosci 13 2 4 20033077 10.1038/nn0110-2 1:CAS:528:DC%2BD1MXhs1SktbnM
11. MF Green 1996 What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 321 330 8610818 1:STN:280:DyaK287otVGqtA%3D%3D (Pubitemid 26074706)
12. JE Hallak SM Dursun DC Bosi LR de Macedo JP Machado-de-Sousa J Abrão JA Crippa P McGuire JH Krystal GB Baker AW Zuardi 2011 The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects Prog Neuropsychopharmacol Biol Psychiatry 35 198 202 21062637 10.1016/j.pnpbp.2010.11.002 1:CAS:528:DC%2BC3MXjsFSktg%3D%3D
13. K Heekeren J Daumann A Neukirch C Stock W Kawohl C Norra TD Waberski E Gouzoulis-Mayfrank 2008 Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis Psychopharmacology 199 77 88 18488201 10.1007/s00213-008-1129-4 1:CAS:528:DC%2BD1cXnvVKgsrs%3D
14. M Herkenham AB Lynn MD Little MR Johnson LS Melvin BR de Costa KC Rice 1990 Cannabinoid receptor localization in brain Proc Natl Acad Sci USA 87 1932 1936 2308954 10.1073/pnas.87.5.1932 1:CAS:528:DyaK3cXhsFWktLs%3D
15. MA Huestis SJ Boyd SJ Heishman KL Preston D Bonnet G Le Fur DA Gorelick 2007 Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users Psychopharmacology 194 505 515 17619859 10.1007/s00213-007-0861-5 1:CAS:528:DC%2BD2sXhtVynur7E (Pubitemid 47492992)
16. DC Javitt M Steinschneider CE Schroeder JC Arezzo 1996 Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia Proc Natl Acad Sci USA 93 11962 11967 8876245 10.1073/pnas.93.21.11962 1:CAS:528:DyaK28XmtlaksLk%3D (Pubitemid 26347231)
17. JD Jentsch RH Roth 1999 The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 201 225 10063482 10.1016/S0893-133X(98)00060-8 1:CAS:528:DyaK1MXhsleisrs%3D (Pubitemid 29067401)
18. G Juckel P Roser T Nadulski J Gallinat AM Stadelmann 2007 Acute effects of delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity Schizophr Res 97 109 117 17884351 10.1016/j.schres.2007.08.015 (Pubitemid 350088400)
19. KM Jung R Mangieri C Stapleton J Kim D Fegley M Wallace K Mackie D Piomelli 2005 Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors Mol Pharmacol 68 1196 1202 16051747 10.1124/mol.105.013961 1:CAS:528:DC%2BD2MXhtF2it7rP (Pubitemid 41539977)
20. S Kähkönen J Ahveninen IP Jääskeläinen S Kaakkola R Näätänen J Huttunen E Pekkonen 2001 Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study Neuropsychopharmacology 25 498 504 11557163 10.1016/S0893-133X(01)00255-X (Pubitemid 32830954)
21. S Kähkönen J Ahveninen E Pekkonen S Kaakkola J Huttunen RJ Ilmoniemi IP Jääskeläinen 2002 Dopamine modulates involuntary attention shifting and reorienting: an electromagnetic study Clin Neurophysiol 113 1894 1902 12464326 10.1016/S1388-2457(02)00305-X (Pubitemid 35441056)
22. S Kapur P Seeman 2002 NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia Mol Psychiatry 7 837 844 12232776 10.1038/sj.mp.4001093 1:CAS:528:DC%2BD38XntVaitb4%3D
23. I Katona GM Urban M Wallace C Ledent KM Jung D Piomelli K Mackie TF Freund 2006 Molecular composition of the endocannabinoid system at glutamatergic synapses J Neurosci 26 5628 5637 16723519 10.1523/JNEUROSCI.0309-06.2006 1:CAS:528:DC%2BD28XlsVOjsb4%3D (Pubitemid 44315254)
24. A Köfalvi ES Vizi C Ledent B Sperlagh 2003 Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action Eur J Neurosci 18 1973 1978 14622229 10.1046/j.1460-9568.2003.02897.x (Pubitemid 37372379)
25. A Köfalvi RJ Rodrigues C Ledent K Mackie ES Vizi RA Cunha B Sperlagh 2005 Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis J Neurosci 25 2874 2884 15772347 10.1523/JNEUROSCI.4232-04.2005 (Pubitemid 40389245)
26. M Korostenskaja D Kicić S Kähkönen 2008 The effect of methylphenidate on auditory information processing in healthy volunteers: a combined EEG/MEG study Psychopharmacology 197 475 486 18264697 10.1007/s00213-007-1065-8 1:CAS:528:DC%2BD1cXjsFOnu7g%3D
27. I Kreitschmann-Andermahr T Rosburg U Demme E Gaser H Nowak H Sauer 2001 Effect of ketamine on the neuromagnetic mismatch field in healthy humans Cogn Brain Res 12 109 116 10.1016/S0926-6410(01)00043-X 1:CAS:528: DC%2BD3MXlslGgu74%3D (Pubitemid 32728286)
28. JH Krystal LP Karper JP Seibyl GK Freeman R Delaney JD Bremner GR Heninger MB Bowers Jr DS Charney 1994 Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 199 214 8122957 1:CAS:528:DyaK2cXkslemtrY%3D (Pubitemid 24081509)
29. JH Krystal DC D'Souza D Mathalon E Perry A Belger R Hoffman 2003 NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development Psychopharmacology 169 215 233 12955285 10.1007/s00213-003-1582-z 1:CAS:528:DC%2BD3sXnvVCgtrc%3D (Pubitemid 37264943)
30. JH Krystal EB Perry R Gueorguieva A Belger SH Madonick A Abi-Dargham TB Cooper L Macdougall W Abi-Saab DC D'Souza 2005 Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function Arch Gen Psychiatry 62 985 994 16143730 10.1001/archpsyc.62.9.985 1:CAS:528: DC%2BD2MXhtVGgtrvK (Pubitemid 41248378)
31. S Leung RJ Croft T Baldeweg PJ Nathan 2007 Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects Psychopharmacology 194 443 451 17611739 10.1007/s00213-007-0865-1 1:CAS:528:DC%2BD2sXhtVynur%2FN (Pubitemid 47492996)
32. S Leung RJ Croft V Guille K Scholes BV O'Neill KL Phan PJ Nathan 2010 Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants Psychopharmacology 208 233 244 20012022 10.1007/s00213-009-1723-0 1:CAS:528:DC%2BD1MXhsFChtbbJ
33. T Lundqvist 2005 Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions Pharmacol Biochem Behav 81 319 330 15925403 10.1016/j.pbb.2005.02.017 1:CAS:528:DC%2BD2MXlt1Gguro%3D (Pubitemid 40807130)
34. AK Malhotra DA Pinals H Weingartner K Sirocco CD Missar D Pickar A Breier 1996 NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 301 307 8703299 10.1016/0893-133X(95)00137-3 1:CAS:528:DyaK28XivVGltbk%3D (Pubitemid 26151927)
35. OJ Mason CJM Morgan A Stefanovic HV Curran 2008 The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis Schizophr Res 103 138 142 18387788 10.1016/j.schres.2008.02.020
36. HY Meltzer L Arvanitis D Bauer W Rein, et al. 2004 Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder Am J Psychiatry 161 975 984 15169685 10.1176/appi.ajp.161.6.975 (Pubitemid 38735983)
37. R Näätänen 1995 The mismatch negativity: a powerful tool for cognitive neuroscience Ear Hear 16 6 18 7774770 10.1097/00003446-199502000- 00002
38. R Näätänen P Paavilainen H Tiitinen D Jiang K Alho 1993 Attention and mismatch negativity Psychophysiology 30 436 450 8416070 10.1111/j.1469-8986.1993.tb02067.x (Pubitemid 23250117)
39. JW Newcomer NB Farber V Jevtovic-Todorovic G Selke AK Melson T Hershey S Craft JW Olney 1999 Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis Neuropsychopharmacology 20 106 118 9885791 10.1016/S0893-133X(98)00067-0 1:CAS:528:DyaK1MXjvFKmsw%3D%3D (Pubitemid 29010370)
40. RC Oldfield 1971 The assessment and analysis of handedness: the Edinburgh inventory Neuropsychologia 9 97 113 5146491 10.1016/0028-3932(71)90067-4 1:STN:280:DyaE387msVSqsQ%3D%3D
41. JW Olney NB Farber 1995 Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 998 1007 7492260 1:CAS:528:DyaK28XotF2rtA%3D%3D
42. JW Olney JW Newcomer NB Farber 1999 NMDA receptor hypofunction model of schizophrenia J Psychiatr Res 33 523 533 10628529 10.1016/S0022-3956(99)00029-1 1:STN:280:DC%2BD3c%2Fpt1Wisg%3D%3D
43. B Oranje BNM van Berckel C Kemner JM van Ree RS Kahn MN Verbaten 2000 The effects of a sub-anaesthetic dose of ketamine on human selective attention Neuropsychopharmacology 22 293 302 10693157 10.1016/S0893-133X(99)00118-9 1:CAS:528:DC%2BD3cXhtFagtLg%3D (Pubitemid 30089540)
44. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity Mol Pharmacol 54 1064 1072 9855635 1:STN:280:DyaK1M%2FnsVemtg%3D%3D (Pubitemid 29002050)
45. PN Patel R Pathak 2007 Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity Am J Health Syst Pharm 64 481 489 17322160 10.2146/060258 1:CAS:528:DC%2BD2sXjsF2nsbw%3D (Pubitemid 46339261)
46. E Pekkonen J Hirvonen J Ahveninen S Kähkönen S Kaakkola J Huttunen IP Jääskeläinen 2002 Memory-based comparison process not attenuated by haloperidol: a combined MEG and EEG study Neuroreport 13 177 181 10.1097/00001756-200201210-00040 (Pubitemid 34102051)
47. EB Perry JA Cramer HS Cho IL Petrakis LP Karper A Genovese E O'Donnell JH Krystal DC D'Souza 2007 Psychiatric safety of ketamine in psychopharmacology research Psychopharmacology 192 253 260 17458544 10.1007/s00213-007-0706-2 1:CAS:528:DC%2BD2sXkslWgsb8%3D (Pubitemid 46669207)
48. TW Picton S Bentin P Berg E Donchin SA Hillyard R Johnson Jr GA Miller W Ritter DS Ruchkin MD Rugg MJ Taylor 2000 Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria Psychophysiology 37 127 152 10731765 10.1111/1469-8986.3720127 1:STN:280:DC%2BD3c7ps1eitg%3D%3D (Pubitemid 30140280)
49. JA Pratt C Winchester A Egerton SM Cochran BJ Morris 2008 Modelling prefrontal cortex deficits in schizophrenia: implications for treatment Br J Pharmacol 153 S465 S470 18311160 10.1038/bjp.2008.24 1:CAS:528: DC%2BD1cXislSjurY%3D (Pubitemid 351341020)
50. M Rinaldi-Carmona F Barth M Héaulme D Shire B Calandra C Congy S Martinez J Maruani G Néliat D Caput, et al. 1994 SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett 350 240 244 8070571 10.1016/0014-5793(94)00773-X 1:CAS:528:DyaK2cXmsVKjsrw%3D (Pubitemid 24268029)
51. P Roser B Della C Norra I Uhl M Brüne G Juckel 2010 Auditory mismatch negativity deficits in long-term heavy cannabis users Eur Arch Psychiatry Clin Neurosci 260 491 498 20127103 10.1007/s00406-010-0097-y
52. P Roser FX Vollenweider W Kawohl 2010 Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists World J Biol Psychiatry 11 208 219 20218784 10.3109/15622970801908047
53. P Seeman HC Guan 2008 Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia Synapse 62 819 828 18720422 10.1002/syn.20561 1:CAS:528:DC%2BD1cXhtF2jtb7I
54. P Seeman F Ko T Tallerico 2005 Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics Mol Psychiatry 10 877 883 15852061 10.1038/sj.mp.4001682 1:CAS:528:DC%2BD2MXovVOgurg%3D (Pubitemid 43080122)
55. P Seeman HC Guan H Hirbec 2009 Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil Synapse 63 698 704 19391150 10.1002/syn.20647 1:CAS:528:DC%2BD1MXnslGisLc%3D
56. DV Sheehan Y Lecrubier KH Sheehan P Amorim J Janavs E Weiller T Hergueta R Baker GC Dunbar 1998 The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 59 S22 S33
57. M Shen SA Thayer 1998 Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity Mol Pharmacol 54 459 462 9730904 1:CAS:528:DyaK1cXmtlGisL0%3D (Pubitemid 28442938)
58. M Shen SA Thayer 1999 Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture Mol Pharmacol 55 8 13 9882692 1:CAS:528:DyaK1MXjs1KnsA%3D%3D (Pubitemid 29042516)
59. M Shen TM Piser VS Seybold SA Thayer 1996 Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures J Neurosci 16 4322 4334 8699243 1:CAS:528:DyaK28Xktlanu7s%3D (Pubitemid 26243028)
60. N Solowij PT Michie 2007 Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32 30 52 17245472
61. NR Swerdlow MA Geyer 1998 Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia Schizophr Bull 24 285 301 9613626 1:STN:280:DyaK1c3ntlKrsA%3D%3D (Pubitemid 28404986)
62. BI Turetsky ME Calkins GA Light A Olincy AD Radant NR Swerdlow 2007 Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures Schizophr Bull 33 69 94 17135482 10.1093/schbul/sbl060 (Pubitemid 46026260)
63. D Umbricht S Krljes 2005 Mismatch negativity in schizophrenia: a meta-analysis Schizophr Res 76 1 23 15927795 10.1016/j.schres.2004.12.002 (Pubitemid 40824557)
64. D Umbricht L Schmid R Koller FX Vollenweider D Hell DC Javitt 2000 Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia Arch Gen Psychiatry 57 1139 1147 11115327 10.1001/archpsyc.57.12. 1139 1:CAS:528:DC%2BD3MXhsFah
65. D Umbricht R Koller L Schmid A Skrabo C Grübel T Huber H Stassen 2003 How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry 53 1120 1131 12814863 10.1016/S0006-3223(02) 01642-6 (Pubitemid 36695087)
66. DS Umbricht JA Bates JA Lieberman JM Kane DC Javitt 2006 Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia Biol Psychiatry 59 762 772 16497277 10.1016/j.biopsych.2005.08.030
67. D Vigano C Guidali S Petrosino N Realini T Rubino V Di Marzo D Parolaro 2009 Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia Int J Neuropsychopharmacol 12 599 614 18789179 10.1017/S1461145708009371 1:CAS:528:DC%2BD1MXlslCjtLs%3D
68. TD Waberski I Kreitschmann-Andermahr W Kawohl F Darvas Y Ryang R Gobbele H Buchner 2001 Spatio-temporal source imaging reveals subcomponents of the human auditory mismatch negativity in the cingulum and right inferior temporal gyrus Neurosci Lett 308 107 110 11457571 10.1016/S0304-3940(01)01988-7 1:CAS:528:DC%2BD3MXltF2jsrg%3D (Pubitemid 32703679)
69. J Wieber R Gugler JH Hengstmann HJ Dengler 1975 Pharmacokinetics of ketamine in man Anaesthesist 24 260 263 1155748 1:STN:280:DyaE2M3itlSqtw%3D%3D